Prostaglandins are endogenously produced compounds that exert their effects in many different areas of the body. There are numerous indications for prostaglandins that include, but are not limited to :
Prostaglandins get produced in the body via the fatty acid arachidonic acid. Initially, arachidonic acid is created when the enzyme phospholipase A2 cleaves the lipid diacylglycerol into the molecule arachidonic acid. Cyclooxygenase enzymes then produce prostaglandins from arachidonic acid via sequential oxidation of each compound. The COX-1 enzyme produces basal amounts of prostaglandins, while chemical mediators induce the COX-2 isoform to increase prostaglandins production. Prostaglandins are highly lipophilic molecules that enter cells via a special prostaglandin transporter, called PGT (prostaglandin transporter). There, they bind to prostaglandin receptors to exert their effects.
There are currently nine known prostaglandin receptors in the body on which prostaglandins exert their effects. All prostaglandin receptors are members of the G-protein coupled receptor signaling family. As members of the G-protein signaling family, prostaglandins can activate secondary signaling pathways by activating or inhibiting enzymes such as adenyl cyclase and phospholipase C, causing downstream effects.
Through these prostaglandin receptors, prostaglandins can cause many effects in almost every part of the body. Prostaglandins can cause vasodilation or vasoconstriction in vascular smooth muscle cells, activate or inhibit platelet aggregation, induce labor, regulate hormones, and decrease intraocular pressure. They can also act in the central nervous system to cause fever and influence pain perception. In the stomach, prostaglandins can act on gastric parietal cells to inhibit acid secretion, as well. In the eye, prostaglandins act to increase the uveoscleral outflow of the aqueous humor by various mechanisms, such as causing the relaxing of ciliary smooth muscle cells. In menstruation, the destruction of endometrial cells release prostaglandins responsible for uterine contractions to release the uterine lining.
There are a variety of means by which to administer prostaglandins to patients. For the treatment of glaucoma and ocular hypertension, synthetic prostaglandin analogs such as travoprost can be administered topically via an eyedropper. For maintaining a patent ductus arteriosus in infants with cyanotic heart disease, such as transposition of the great arteries and truncus arteriosus, alprostadil (PGE1) can be given intravenously thru a large vein or directly thru the umbilical vein. Oral or injected alprostadil is also an option in the treatment of erectile dysfunction. PGF2 alpha can be applied vaginally or intramuscularly to induce abortion in pregnant patients. In some cases, misoprostol (PGE1) can be used rectally for the treatment of postpartum hemorrhage. Iloprost, a PGI2 analog, can be inhaled to treat pulmonary hypertension and CREST syndrome.
The route of administration of the prostaglandin analog can determine the side effects the patient might experience. Continuous infusion of prostaglandin may place the patient at risk for catheter infections, while an injected prostaglandin analog may cause a local site infection or pain at the injection site.
Topical latanoprost has very limited systemic side effects, but over time the drug may cause iris darkening, eyelash thickening, periocular skin pigmentation, and conjunctival hyperemia. Systemically administered prostaglandins are usually tolerated reasonably well, but there may some side effects such as fever, hypotension, musculoskeletal pain, and cough. Vaginally administered prostaglandins may cause symptoms such as nausea, vomiting, flushing, fever, back pain, diarrhea, and abdominal pain. When using alprostadil for erectile dysfunction, serious side effects such as priapism can occur as well. Misoprostol, when used to treat gastric ulcers, can induce abortion in pregnant patients.
Depending on the treatment and indication, there can be a variety of contraindications for prostaglandin therapy. One major contraindication to prostaglandin therapy is hypersensitivity to the drug. The use of misoprostol for gastric ulcer treatment is contraindicated in prepartum pregnant patients because misoprostol causes cervical ripening and can induce abortion. Alprostadil for treating erectile dysfunction is contraindicated in patients with sickle cell disease, polycythemia vera, thrombocytosis, and multiple myeloma because these conditions can even further the risk of priapism. Clinicians should also exercise caution when using alprostadil in patients with Peyronie disease as alprostadil may increase the risk for penile fibrosis. The prostaglandin epoprostenol should be used with caution in patients with heart failure, as well.
Depending on the treatment, there need to be different approaches to the monitoring of prostaglandin therapy. In general, systemic symptoms such as hypotension and fever should be kept in mind as prostaglandin therapy can lead to these side effects. For the treatment of pulmonary hypertension, the prostaglandin dosing requires slow titration to monitor for side effects, and the pulmonary artery blood pressures should be checked to confirm proper response to the treatment. For glaucoma, the intraocular pressure should be rechecked biweekly or monthly to ensure the achievement of the target intraocular pressure. When using alprostadil therapy for erectile dysfunction, the healthcare team can monitor for alprostadil-related side effects such as hematoma and urethral stricture formation. The healthcare team can also converse with the patient to ensure that they achieve the response that they were expecting and are content with the therapy.
The toxicity of prostaglandins depends on the therapy chosen. In general, most prostaglandins are well tolerated with limited toxicity. There is no known antidote for overdose of prostaglandins. In cases of suspected prostaglandin overdose, discontinue the drug and provide supportive care to alleviate signs such as flushing. In the case of alprostadil-induced priapism, surgical intervention such as cavernosal blood aspiration or injection of cold saline can be used to mitigate the side effect.
In patients receiving prostaglandin therapy, there needs to be an interprofessional healthcare team effort to ensure maximum therapeutic response and safety outcomes. After a provider prescribes a prostaglandin analog, nurses and pharmacists should educate patients on the proper administration technique of the drug and any side effects that they may experience as a result of taking it. Clinicians and pharmacists should review the patient's medication list to ensure no drug-to-drug interactions to maximize the drug's therapeutic potential. Interprofessional collaboration between the clinician prescriber and pharmacist maximizes success and reduces adverse outcomes for prostaglandin therapy. [Level 5]
|||Miller SB, Prostaglandins in health and disease: an overview. Seminars in arthritis and rheumatism. 2006 Aug; [PubMed PMID: 16887467]|
|||Korbecki J,Baranowska-Bosiacka I,Gutowska I,Chlubek D, Cyclooxygenase pathways. Acta biochimica Polonica. 2014; [PubMed PMID: 25343148]|
|||Schuster VL,Chi Y,Lu R, The Prostaglandin Transporter: Eicosanoid Reuptake, Control of Signaling, and Development of High-Affinity Inhibitors as Drug Candidates. Transactions of the American Clinical and Climatological Association. 2015; [PubMed PMID: 26330684]|
|||Hata AN,Breyer RM, Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacology [PubMed PMID: 15369681]|
|||Bernardi M,Lazzeri L,Perelli F,Reis FM,Petraglia F, Dysmenorrhea and related disorders. F1000Research. 2017; [PubMed PMID: 28944048]|
|||Razeghinejad MR, The Effect of Latanaprost on Intraocular Inflammation and Macular Edema. Ocular immunology and inflammation. 2019; [PubMed PMID: 29028372]|
|||Akkinapally S,Hundalani SG,Kulkarni M,Fernandes CJ,Cabrera AG,Shivanna B,Pammi M, Prostaglandin E1 for maintaining ductal patency in neonates with ductal-dependent cardiac lesions. The Cochrane database of systematic reviews. 2018 Feb 27; [PubMed PMID: 29486048]|
|||Krishna U,Ganguli AC,Mandlekar AV,Purandare VN, Administration of prostaglandins by various routes for induction of abortion. Merits and demerits. Prostaglandins. 1978 Apr; [PubMed PMID: 674699]|
|||Alm A,Grierson I,Shields MB, Side effects associated with prostaglandin analog therapy. Survey of ophthalmology. 2008 Nov; [PubMed PMID: 19038628]|
|||Kingman M,Archer-Chicko C,Bartlett M,Beckmann J,Hohsfield R,Lombardi S, Management of prostacyclin side effects in adult patients with pulmonary arterial hypertension. Pulmonary circulation. 2017 Jul-Sep; [PubMed PMID: 28632002]|
|||McLaughlin J,Devoe LD, Current Status of Prostaglandins for Cervical Ripening. The Journal of reproductive medicine. 2017 May-Jun; [PubMed PMID: 30027713]|
|||Tang OS,Gemzell-Danielsson K,Ho PC, Misoprostol: pharmacokinetic profiles, effects on the uterus and side-effects. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2007 Dec; [PubMed PMID: 17963768]|
|||Costa P,Potempa AJ, Intraurethral alprostadil for erectile dysfunction: a review of the literature. Drugs. 2012 Dec 3; [PubMed PMID: 23170913]|